Study raises new questions about Merck pill Zetia


  • Business Premium
  • Monday, 16 Nov 2009

ORLANDO, Florida (AP): A new study raises fresh concerns about Zetia and its cousin, Vytorin - drugs that are still taken by millions of people to lower cholesterol, despite questions raised last year about how well they work.

In the study, Zetia, the brand name for ezetimibe, failed to shrink buildups in artery walls while a rival drug, Niaspan, generically known as niacin, did so significantly. Zetia users also suffered more heart attacks and other problems although the numbers of these events are too small to draw firm conclusions.

Article type: metered
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights
   

Next In Business News

Hibiscus Petroleum's 3Q net profit jumps to RM307.54mil, declares 1c div per share Premium
T7 Global posts net profit of RM2.72mil in 1Q Premium
Malaysia's recovery continues to be resilient, March's LI up to 111.3 points Premium
Bumi Armada posts improved 1Q net profit of RM185.76mil Premium
FBM KLCI stays positive as Asia shrugs off Wall St weakness Premium
CPI rises 2.3% in April, with food inflation higher at 4.1% Premium
Elon Musk drops out of US$200bil club again as Tesla tumbles Premium
Latex goods account for 83.1% of total exports for rubber products in Q1 2022 Premium
Ringgit opens marginally higher as greenback demand eases Premium
Singapore economy expands 3.7% in Q1 2022 Premium

Others Also Read